A recent work stratified GBM patients into Stat3-high and Stat3-low cohorts and showed that Stat3 inhibitors were effective in reducing Stat3-high tumor cell viability and tumorigenicity in mouse xenograft models11. Here, STAT3 is linked to glioblastoma.